| Literature DB >> 28119681 |
Liliana Brito1, Joana Wilton1, María J Ferrándiz2, Alicia Gómez-Sanz1, Adela G de la Campa3, Mónica Amblar1.
Abstract
The transfer messenger RNA (tmRNA), encoded by the ssrA gene, is a small non-coding RNA involved in trans-translation that contributes to the recycling of ribosomes stalled on aberrant mRNAs. In most bacteria, its inactivation has been related to a decreased ability to respond to and recover from a variety of stress conditions. In this report, we investigated the role of tmRNA in stress adaptation in the human pathogen Streptococcus pneumoniae. We constructed a tmRNA deletion mutant and analyzed its response to several lethal stresses. The ΔssrA strain grew slower than the wild type, indicating that, although not essential, tmRNA is important for normal pneumococcal growth. Moreover, deletion of tmRNA increased susceptibility to UV irradiation, to exogenous hydrogen peroxide and to antibiotics that inhibit protein synthesis and transcription. However, the ΔssrA strain was more resistant to fluoroquinolones, showing twofold higher MIC values and up to 1000-fold higher survival rates than the wild type. Deletion of SmpB, the other partner in trans-translation, also reduced survival to levofloxacin in a similar extent. Accumulation of intracellular reactive oxygen species associated to moxifloxacin and levofloxacin treatment was also highly reduced (∼100-fold). Nevertheless, the ΔssrA strain showed higher intracellular accumulation of ethidium bromide and levofloxacin than the wild type, suggesting that tmRNA deficiency protects pneumococcal cells from fluoroquinolone-mediated killing. In fact, analysis of chromosome integrity revealed that deletion of tmRNA prevented the fragmentation of the chromosome associated to levofloxacin treatment. Moreover, such protective effect appears to relay mainly on inhibition of protein synthesis, since a similar effect was observed with antibiotics that inhibit that process. The emergence and spread of drug-resistant pneumococci is a matter of concern and these results contribute to a better comprehension of the mechanisms underlying fluoroquinolones action.Entities:
Keywords: Streptococcus pneumoniae; antibiotic resistance; chromosomal fragmentation; fluoroquinolones; reactive oxygen species; stress adaptation; tmRNA; trans-translation
Year: 2017 PMID: 28119681 PMCID: PMC5222879 DOI: 10.3389/fmicb.2016.02164
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Bacterial strains and plasmids used in this study.
| Bacterial strain | Description | Source |
|---|---|---|
| TIGR4 | Capsular type 4 clinical isolate strain TIGR4 | |
| TIGR4 | TIGR4 | This study |
| TIGR4 | TIGR4 | |
| R6 | Non-encapsulated strain derived from the capsular type 2 clinical isolate strain D39 | Laboratory collection |
| R6 | R6 | This study |
| R6 | R6 | This study |
| R6 | R6 | This study |
| pLS1ROM | ||
| pROM | pLS1ROM lacking PM promoter | This study |
| pROM-TM | pROM containing tmRNA chromosomal fragment | This study |
List of primers used in this study.
| tmRNA-F | TTCTGTGTCAGGGTAAGTTCC | Up PCR fragment for |
| tmRNAKmUp-R | TTATCCATTAAAAATCAAACGGATCACATACCTAAGATGAAGCTATCT | |
| tmRNA-R | ACTGAATCACCTCCTGTTATCG | Down PCR fragment for |
| tmRNAKmDown-F | TACGAGGAATTTGTATCGATGTGGACGTGGGTTCGACT | |
| KmN-F | CCGTTTGATTTTTAATGGATAA | Kmr cassette for |
| KmN-R | CATCGATACAAATTCCTCGTA | |
| pLSROM-F-Xba2 | CGTCTGCAAAATAC | For pROM construction |
| pLSROM-R-Xba2 | CTCACGAGACAG | |
| tmRNACj-F | CGC | For |
| tmRNACj-R | GCGC | |
| tmRNA-1 | AATTATCCTGCGCTCCAGAA | For |
| tmRNA-2 | TTTCAAGACACGGCTGACA |
Doubling time of pneumococcal strains used.
| 37°C | 30°C | |
|---|---|---|
| TIGR4 | 42.8 ± 1.9 | n.d. |
| TIGR4 | 61.7 ± 2.4 | n.d. |
| R6 | 48.6 ± 0.9 | 65.4 ± 1.0 |
| R6 | 62.2 ± 2.2 | 95.7 ± 4.5 |
| R6 | 85.4 ± 5.6 | 108.1 ± 10.1 |
| R6 | 41.0 ± 2.4 | 68.6 ± 1.5 |
In vitro antibiotic susceptibilities determined by macrodilution in TIGR4 and R6 strains of Streptococcus pneumoniae.
| TIGR4 | TIGR4 | R6 | R6 | ||
|---|---|---|---|---|---|
| Chloramphenicol | 1 | 0.5 | n.d. | n.d. | 2 ↓ |
| Tetracycline | 0.125 | 0.062 | n.d. | n.d. | 2 ↓ |
| Erythromycin | 0.03 | 0.0075 | n.d. | n.d. | 4 ↓ |
| Rifampicin | 0.06 | 0.03 | n.d. | n.d. | 2 ↓ |
| Penicillin | 0.016 | 0.016 | n.d. | n.d. | |
| Cefotaxime | 0.015 | 0.015 | n.d. | n.d. | |
| Moxifloxacin | 0.25 | 0.50 | 0.125 | 0.25 | 2 |
| Levofloxacin | 0.50 | 1 | 0.25 | 0.50 | 2 |
| Ciprofloxacin | n.d. | n.d. | 0.50 | 1 | 2 |
| Norfloxacin | n.d. | n.d. | 4 | 8 | 2 |